HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis

Human Pathology

Volumn 42, Issue 6, 2011, Pages 909-910

  Negri, Francesca V ^a   Bozzetti, Cecilia ^a   Ardizzoni, Andrea ^a   Lagrasta, Costanza ^a   Crafa, Pellegrino ^a   Silini, Enrico M ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; TRASTUZUMAB; TRASTUZUMAB PLUS CISPLATIN; UNCLASSIFIED DRUG;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LETTER; LYMPH NODE METASTASIS; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOMA;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; FLUOROURACIL; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79956150965     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.01.016     Document Type: Letter

References (3)

1. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. HUM PATHOL 2009;40:769-77.
2. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. (Pubitemid 351724903)
3. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.